News TMC inches closer to inclisiran approval with long-term safe... The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal tria
News Merck axes cholesterol drug despite phase 3 success Merck & Co has said it will not file anacetrapib with regulators
News Court bans US sales of Sanofi cholesterol drug Amgen looks to corner PCSK9 market after patent win.
News Pfizer's hopes for cholesterol blockbuster dashed Sales of cancer drug Ibrance also fall short of expectations.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.